title: CD4+ CD56+ hematodermic neoplasm and plasmacytoid dendritic cell tumor: case report and review of the literature.
abstract: CD4+ CD56+ hematodermic neoplasm (HN) is a rare and aggressive neoplasm that has raised controversy regarding its etiology. CD4+ CD56+ HN is thought to be derived from plasmacytoid dendritic cells (pDCs) and most commonly stains with CD4, CD56, CD123, and T-cell leukemia/lymphoma 1 (TCL1). Skin manifestations usually are the presenting signs and vary in appearance. Lymph node involvement also is common at the time of presentation, and the natural course of the disease is a progression to leukemia. Treatment of CD4+CD56+ HN focuses on multiple chemotherapeutic regimens but none have been proven to successfully impact overall survival.
authors: Division of Dermatology, The Ohio State University, Columbus 43221, USA. shannon.campbell@osumc.edu
authors: Shannon M
authors: SM
authors: Campbell
authors: John C
authors: JC
authors: Moad
authors: Dawn L
authors: DL
authors: Sammons
authors: Matthew
authors: M
authors: Zirwas
mesh_terms: D000368:Aged; D015704:CD4 Antigens / Q000276:immunology; D019002:CD56 Antigen / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology*; D003937:Diagnosis, Differential; D018450:Disease Progression; D005260:Female; D019337:Hematologic Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000473:pathology*; D006801:Humans; D012878:Skin Neoplasms / Q000175:diagnosis / Q000276:immunology / Q000473:pathology*
chemical_list: D015704:CD4 Antigens; D019002:CD56 Antigen